APA (7th ed.) Citation

KG, S., N, P., P, G., JD, A., OD, M., J, M., . . . WF, L. (2019). Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial. Arthritis & rheumatology (Hoboken, N.J.), 71(7), 1174. https://doi.org/10.1002/art.40874

Chicago Style (17th ed.) Citation

KG, Saag, et al. "Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial." Arthritis & Rheumatology (Hoboken, N.J.) 71, no. 7 (2019): 1174. https://doi.org/10.1002/art.40874.

MLA (9th ed.) Citation

KG, Saag, et al. "Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial." Arthritis & Rheumatology (Hoboken, N.J.), vol. 71, no. 7, 2019, p. 1174, https://doi.org/10.1002/art.40874.